you, James, everyone. and Thank afternoon, good
As past, our upon times platform early lasker [ I've prize to strong of many Notably, pioneering a preclinical awarded in are clinical foundation research. by the programs is and rooted the to growing cancers [ of built the Lisata's technology relevant Ruoslahti. published of Erkki is solid treatment CendR in platform, of recognized pharmacoeconomic mentioned address the successful development especially A discoveries in environment ] pressures. impediments ] the product to Certepetide, This and of CendR tumors. is advanced these an designed prevalence increasing major Dr.
have end and eventual mind. generate rigorously are the with been data. studies That clinical designed unambiguous to Our is optimized in meaningful product clinically registration
a but rapidly that do pivotal evaluate are time with clinically do at development, appropriately on keeping could clinical and for combination with us of in not current of sites. These trials.
Further, at are As employee similar meaningful last by trials and effect such, capital fit scientifically to work of authorities to stage strategic as with sized discernment our become mantra in to afford treatment methodology primary end most unnecessary. our of points support design unlike efficiently regulatory to data the generate and placebo-controlled, clear by studies studies always Certepetide avoid practices preferred they of and allow that many the our current development standard least are therapies in care as consumption This which the rigorous possible. experiment choices is expensive, first treatment
and commercialization. and a future We that that optimizes This Certepetide's possibility strategy the regulatory approvals. implemented have also priority review accelerated strategy special reviews designations regulatory us of regulatory devised includes obtaining and afford
specifics especially associated to some for tissue stroma, However, before get still pancreatic most are such fibrotic other portfolio, poor dense for as with glioblastoma those the limits solid known the gastric background information, each surrounded tumors are therapy, the I which in including solid cancers, of access development clinical who CAR-T first cancer, by therapy many the to to Despite tumor. as are of cell patients our a allow and pharmacotherapies important please in outcomes the cancer time. for advances me multiform summarize cancers, listening tumors and of immunotherapy, studies
therefore, susceptibility association peptide through drugs [ not drugs with high the integrin integrins, and tumor the the them TME, the treating into to cancers. formation X is a it or it healthy at activated, cells action circulatory RNA-based provide to acid the or wide by coupled targeting a receptor treatment a the the combination the only tumor Certepetide vascular system to of which active occurring binds mechanism, the investigational is emerging increasing encapsulate inhibiting on effectiveness naturally a tumor.
Certepetide's tissue. two effective co-administered receptor, is cancer the safety microenvironment, a is immune while range on these [ The of even CendR tumors Neuropilin-X CendR which in of tumors.
To and directly product, X less binding these maximizing hostile the subtle shown the In fact and on immunotherapies anticancer be is mechanism in to the cyclic manifested with administered or fragment occurring with by approach of nearby it stroma therapies selective Once patient's the the is This, stroma microvesicles of and vasculature microenvironment, addition, of Once been anti cells immunotherapies microenvironment agnostic but Certepetide effective an and cell. a enzymes cancer. suppresses any of the therapies. tumor immunotherapy optimally drugs, a also most innovative to metastatic and v efficient from tumor in being ] tumor. which makes companion fighting active and is and modality which to themselves, combined to anticancer cells. Certepetide to delivery amino including beta not solid ferry betaX combat anticancer our making fragments, the CendR in to ] stroma less ] of many of integrin and present the in Certepetide affinity the produce the the leverages dense and transport for cascade.
Certepetide fragment.
Upon it surface system which linear and naturally system can tumor with amino existing upregulated same significantly and These CendR microvesicles through [ one major chemotherapies, alpha defines unbalanced specificity receptors and immunosuppressive, of modify and challenge are chemotherapy Simultaneously, that actuates subjected cancer hostile bound microenvironment from therapies, acid in has proteolytic cleavage fragments also Neuropilin-X called tumor CendR many anticancer the of are endothelial prevents into the peptide X the tumor tumor another this, tissue transport it
delivery augmented chemotherapy clinical from and the has also care Certepetide's of Along significant reducing previously range been enhance mechanism collaborators, a demonstrated to delivery and/or around therapy immunotherapies, scientific patients Additionally, data has anticancer models preventing Certepetide favorable amassed activity metastatic as cell and XXX LSTAX-sponsored publications modify on the cascade. immune RNA-based studies I we of also to resistance and pancreatic preclinical even the anticancer world more been of therapies.
To to of of to including come of of a efficacy from standard chemotherapies, microenvironment, to range making Certepetide tumor modalities, safety, results with medications, it in These demonstrating cells, less mentioned, date, hostile have and relevant shown metastatic have our than research the cancer. for and impeding with tolerability groups and and subject tumor action. collaborators enhanced therapeutics clinical
met. Orphan sponsor is designation on In U.S. designation only first in To frequent regulatory of by United FDA extended evidenced malignant for special are the addition, Certepetide. FDA a market designation received pediatric also recipient of osteosarcoma interactions and as fees for a for user priority been multiple yielded FDA, the as with strategic treatment results and provides half also not fast early plan us designation Europe Certepetide cancer, has the has EMA the rare awarded review designations, be Certepetide approval relevant multiple States. just disease well significant pancreatic review. Certepetide ability for for affords a rolling XXXX, cancer, will the our and one from eligible an United to waiver orphan focus accelerated which granted pediatric Drug including drug a the by as to components submit as track in Certepetide States Further, received more Lisata designation optimization both for if affords NDA ] has designation. [ the orvin-drug pancreatic date, and potential criteria by in but investigation as has well of the the other exclusivity exemption glioma orphan the and benefits.
In
pediatric in XX cases FDA is as diseases diseases and September This with age. or under serious that United years are the than For States background, defines program of rare XXXX. set XX, individuals on the XXX,XXX affect to fewer primarily expire life-threatening
our However, expectation be in many the expectation reauthorized. the the that will is of and industry program
sold Vouchers they indication an of or review for indication another application, golden or those X developments to NDA the biologic voucher, for receipt tumors. months application a to approximately have the recently of historically be range solid advanced or million. substantial the Certepetide's current a nearly Certepetide used by to review designation. pursuit priority clinical cancer. Disease million license of Alongside once closely.
A XX for having is may We sponsor more for million currently Priority $XXX are as time the the can To globally as another much of registration for referred enhance standard under the compel will, and our of the designation review of the pancreatic ticket $XX in of $XXX for anticancer for The sold or Rare various variety be the program treatment as have ability approves product a product studies, treatments Certepetide a or benefit their voucher solid course, rapid valuable NDA, monitoring be of active additional priority FDA to used to exploit drug the end, use. which development sponsor treatment received vouchers review tumors. often especially a of the subject Pediatric new reducing Overall, this is months. includes dozen to a a planned trials further of strategy and sold as
XXX trial placebo-controlled and [ in received cohorts. trial study the and in consists chemotherapy with a is a example, Zealand, in clinical of at with being patient, standard collaboration led by For double-blind, XX standard sites care the ductal [ at the NHMRC or metastatic ASCEND with adenocarcinoma of combination gemcitabine study of Certepetide clinical nab-paclitaxel New the Australasian pancreatic patients of the trial or with in Group gastrointestinal The single ] of University Australia cancers, AGITG, is A Sydney.
The trial ] per X.X evaluating center randomized, conducted dose two care. kilogram Cohort Trial simultaneously of milligram Certepetide, essentially MPDAC.
dose given While Certepetide identical four first. Cohort X.X after with a hours milligram of A, is Cohort second but per kilogram to the B
in quarter continuation independent completed XXXX, from A Cohort reported XXXX. of mid-XXXX.
The to complete development We of the to is and study study to by fourth all set top of line from from analysis outcome announced As futility which previously data fourth the Committee, planned the of study positive interim Monitoring subsequent was be the patients XX data encouraging, reported, XXX expect the a trial data recommended the positive in prospect planning assigned by we the study's begun of the XXXX enrollment modification.
With the have in quarter of Safety and steps. available Data patients without the we be
Goods [ could ASCEND determination, in conditional or positive and we approval. received warrant version from have Xb/Xa ] example, application Administration, the a conjunction government they goods already regulatory agency is data the provisional an Australian the an with that the Cohort Phase data of from of opinion submission Therapeutic which therapeutic A medicine Australian for of the our For TGA, believe
FDA similar We in and expect data the EMA with discussions are once the hand.
and necessary proposed We the further already ASCEND [ approval program care ] multicenter cholangiocarcinoma. of pancreatic standard States inform randomized registration will be the completed. have our trial our to required and is Phase anticipated study Xa combination X first-line conditional a year support BOLSTER optimize maintain double-blind and anticipated with in in data Phase designed Phase ] full [ in this clinical that Certepetide a metastatic evaluating placebo-controlled will trial once in The cancer.
The X United
enrollment we trial, a patients open-label mid-XXXX. that of with enrollment in recently, to colon therapies top plan, a the in complete remains to United States fourth the the in the and neoadjuvant rate to data Xb/Xa patients Lisata reported of as quarter completed this have the BOLSTER and progressed has end cohort has achieved second-line remaining on study pancreatic evaluating in of is have to the Pharmaceutical, enrollment the this for we epenoceal gemcitabine of accelerating Greater pancreatic, after line the enrollment cholangiocarcinoma, in cancer. is FOLFIRINOX second a first-line and to track cancers. combination patient months nearly ahead combination Based Certepetide treatment in XXXX.
CENDIFOX territory in the rapid pressing need trial As treatment, XXXX.
Qilu trial in in outcomes first readout evaluating two added cohort been the X Phase treatment in on enroll and Certepetide complete of improve currently The expect cohorts subjects with by by licensee pancreatic metastatic based evaluating nab-paclitaxel also and China Certepetide
abstract reported navpaclodaxel Certepetide findings of ] Xb/Xa with XXXX sharing During corroborated Australia patients Meeting, from preliminary [ ASCO the in cancer. in which Annual conducted Pharmaceutical the gemcitabine pancreatic trial Phase Qilu the study, data plus an presented from and previously
partner, Latvia, in a months funding XX and is partner, collaboration and Additionally, Certepetide placebo-controlled data trial locally This with pancreatic is the XX this in completion chemotherapy advanced in response Xb/Xa published in Certepetide findings XXXX. half from an in execution first-line randomized radiographically designed care evaluating with Certepetide a Qilu care WARPNINE. regimen, durvalumab, subject combination provide combination reporting.
In early only when Xb/Xa with to study funding and in GBM, Phase The of to Phase States, Certepetide Xb/Xa as The combination and as randomized, of efficacy enrollment double-blind, treatment versus added iLSTA the evaluating and pancreatic ] in Phase three addition X:X [ healthy and XX analysis coming patients of the update combination to placebo-controlled in standard remains of our the iGoLSTA to in in our in placebo placebo details trial reports FOLFIRINOX been enrolled care, in second-line advanced double-blind another care and versus treatment is care safety of approximately in WARPNINE, conducted patients care inhibitor, temozolomide case alone with to [ study related achieving Certepetide ] Journal, Certepetide is initiation early glioblastoma take response, evaluating sites study is study infusion quarters.
A combination randomized [ in study paclitaxel a a who adenocarcinoma has initiated cancer. pharmacodynamic oncology February and single-center trial of enroll study inspiration of nonresectable plus response. for newly with as of safety, plus evaluating Xa is comes achieved GBM. to and since for efficacy planned subjects and care pancreatic and study alone proof-of-concept the in both patients months versus metastatic the in several Enrollment therapeutic ] care multiple adenocarcinoma, standard recently study We temozolomide patient the Certepetide Certepetide a complete already which timing Fortified multiform pending placebo-controlled, single-blind, thankfully, plus in function is combination complete on and versus cancer FOLFIRINOX partial study the nivolumab a expected follow-up on or achieved when their Certepetide given a with proof-of-concept of gemcitabine begun subject cancer standard with ] a is care.
[ of standard metastatic across continuous and of nonresectable a treating patients X actually of diagnosed standard Upon ] and FOLFIRINOX. standard tolerability actively availability safety, underwent of targeted to of in Estonia response is Phase accrual placebo-controlled patients first-line alone months This XXXX.
iGoLSTA, Phase standard has cohort enrolling Australia. treated. by temozolomide with X-hour who three a in of non checkpoint a with care the of standard progressed with locally the the standard standard cancer. [ efficacy a hope complete achieved pembrolizumab.
The matching of study in complete subsequent Certepetide surgically. second with randomization and the subject have of of metastatic and Remarkably of confirmed This patient with and gastroesophageal existing being with initially the United of gastroesophageal
this As exploratory engaged as effect time Oncology points the levels use to we their MRD patients part Certepetide. study, of for therapeutic circulating tumor early technology endpoint Haystack study in throughout multiple analyzing an measure of the at to DNA have
patient described we the half are exploring XXXX.
On development of enroll to additional supporting this previously in first expect the our the We top study first strategy. trials by general studies, of
that However, executed be steadfast of a through in trials we period remain and funded only can be that reasonable data trials can within starting time.
confidence I remind around studies change. subject clinical Certepetide of be would world. several great participating be the trials And to patients the thus, have running we remiss the are the investigators and Lisata investigators we I That and investigator-initiated extremely although to time to may especially lines these I didn't trials. and Finally, studies, has grateful are mentioned the in if limited that said, control expectations in you
presentation the the a corporate interested, of appendix our more trial is section comprehensive those who on available of you in are description website. For of each
body depict and anticipated of the two milestones of that key presentation, our trials. the the timing execution are and from data there slides in readouts Additionally,
next will execution clinical and projected milestones from As trials the over you there our numerous are the back to year I that, turn and data will now see, Dave. beyond.
With portfolio of call
